Please assess the completion status of the following clinical trial:

Trial Title: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, aged 18 and older~* Biopsy-proven metastatic carcinoid tumor of the gastrointestinal (GI) tract with disease extent confirmed by computed tomography (CT), magnetic resonance imaging (MRI), or radionuclide imaging~* Symptoms not managed by stable-dose long-acting octreotide therapy (≥4 bowel movements per day)~* Ability to provide written informed consent~Exclusion Criteria:~* ≥12 high volume, watery bowel movements per day associated with a clinical syndrome of volume contraction, dehydration, or hypotension compatible with a pancreatic cholera-type clinical syndrome~* Sponsor-unacceptable clinical laboratory values for hematology and liver function tests at screening~* Karnofsky status ≤70% - unable to care for self~* Surgery within 60 days prior to screening~* A history of short bowel syndrome~* Life expectancy \<12 months~* History of substance or alcohol abuse within 2 years prior to screening~* Previous exposure to a tryptophan hydroxylase (TPH) inhibitor~* Administration of any investigational drug within 30 days of screening or any therapeutic protein or antibody within 90 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telotristat Etiprate 150 mg Core Phase (Type: EXPERIMENTAL): Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
- Telotristat Etiprate 250 mg Core Phase (Type: EXPERIMENTAL): Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
- Telotristat Etiprate 350 mg Core Phase (Type: EXPERIMENTAL): Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
- Telotristat Etiprate 500 mg Core Phase (Type: EXPERIMENTAL): Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
- Placebo Core Phase (Type: EXPERIMENTAL): Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
- Telotristat Etiprate Open-Label Extension Phase (Type: EXPERIMENTAL): Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).